Figure 7—figure supplement 1.

(A) Adapted dihydropyridine cluster including compounds not represented in the Tocris or Spectrum collections. The new compounds tested are shown as green circles. Nemadipine-A falls just below the threshold of the network analysis performed, illustrated by the dotted line connecting to its closest related compound. (B) Dose-responsive activity of the dihydropyridines in the vcanb assay. (i-xii) Lateral views of the inner ear at four dpf stained for vcanb by ISH; anterior to the left. Controls: (i) wild-type, untreated; (vii) adgrg6^tb233c mutant treated with DMSO as a negative control; (xii) adgrg6^tb233c mutant treated with 100 µM IBMX as a positive control. (ii-vi) Treatment of adgrg6^tb233c mutants with test compounds at a low concentration (25–33.8 µM), (viii-xi) treatment of adgrg6^tb233c mutants with test compounds at a high concentration (40–50.6 µM), (xiii-xvii) Representation of the chemical structure of the five compounds tested. Scale bar in (i), 50 µm (applies to i-xii).